Search
Returning search results with filters:
Remove filter for
Issue: New safety information
Remove filter for
Last updated: 2023
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 5 of 5 items.
IDHIFA (enasidenib mesylate) – Market Withdrawal and Continued Access
AlertHealth professional risk communication | 2023-06-08
ISTODAX (romidepsin) – Restricted Access Program
AlertHealth professional risk communication | 2023-03-20
ZEJULA (niraparib) - Update on the Maintenance Treatment in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in the Second or Later Line Setting
AlertHealth professional risk communication | 2023-02-16
RUZURGI (amifampridine) - Authorization Status
AlertHealth professional risk communication | 2023-01-20
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 Subvariants
AlertHealth professional risk communication | 2023-01-17